Drug profile · INN
insulin recombinant human
HUMULIN R PEN
insulin recombinant human (HUMULIN R PEN) is a insulin receptor agonist. Route of administration: injection. Current US regulatory status: approved.
Drug details — insulin recombinant human
- US status
- approved
- Class
- —
- Route
- INJECTION
- Patents
- 0
- Programs
- 0
- Data quality
- 0.84
Quick answer
insulin recombinant human (HUMULIN R PEN) is a insulin receptor agonist. Route of administration: injection. Current US regulatory status: approved.
Key facts
Mechanism of action
Insulin receptor agonist
Primary target: Insulin receptor
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
Recent coverage
FDA Approves MannKind's Afrezza for Pediatric Diabetes Patients
The US FDA has approved MannKind's Afrezza inhaled insulin for pediatric patients aged 6 and older diagnosed with Type 1 or Type 2 diabetes. This approval marks a significant expansion for the inhaled insulin.
MannKind's Pediatric Expansion: A New Era for Afrezza
MannKind's recent approval of Afrezza for pediatric use marks a significant milestone. This article explores the implications for investors and pharma teams.
Related & competitor drugs
Frequently asked questions
What is insulin recombinant human?
insulin recombinant human (HUMULIN R PEN) is a insulin receptor agonist. Route of administration: injection. Current US regulatory status: approved.
What is the brand name for insulin recombinant human?
HUMULIN R PEN is a marketed brand name for insulin recombinant human. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of insulin recombinant human?
insulin recombinant human has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.